Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04175834 · ClinicalTrials.gov registry record · Phase 3
Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
A Phase 3 study of Multiple Sclerosis and Infusion Reaction, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 3
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT04175834 is a Phase 3 study of Multiple Sclerosis and Infusion Reaction that has completed, run by Providence Health & Services. The registered enrollment target is 19 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04175834, a Phase 3 study of Multiple Sclerosis and Infusion Reaction, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
This 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in Infusion-Related Reactions (IRRs) in subjects receiving ocrelizumab(OCR) for multiple sclerosis (MS).
Conditions Studied
Interventions
- DRUG cetrizine
- DRUG diphenhydramine
Study Locations (1)
Oregon
- Providence Neurological Specialties West - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2020-02-05 |
| Est. Completion | 2022-05-13 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04175834
The ClinicalTrials.gov registry entry for NCT04175834 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (97% lower). The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which cetrizine is the first listed.
NCT04175834 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT04175834 about?
NCT04175834 is a clinical study titled "Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab". This 6-month randomized controlled pilot study will determine whether there is some evidence that cetirizine is better tolerated than diphenhydramine without an increase in Infusion-Related Reactions (IRRs) in subjects receiving ocrelizumab(OCR) for multiple sclerosis (MS).
What is the current status of trial NCT04175834?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 19 participants. The study started on 2020-02-05. Estimated completion is 2022-05-13.
What conditions does trial NCT04175834 study?
This clinical trial studies the following conditions: Multiple Sclerosis, Infusion Reaction.
What interventions are being tested in trial NCT04175834?
The interventions under investigation include: cetrizine (DRUG), diphenhydramine (DRUG).
Who is sponsoring clinical trial NCT04175834?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04175834 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
RECRUITING · Phase 3
-
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
RECRUITING · Phase 3
-
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.